Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309023 · ClinicalTrials.gov registry record · Phase 1
Study of BMS-663513 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
NCT00309023 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 115 participants.
The verdict
NCT00309023, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
Interventions
- DRUG BMS-663513
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309023
The ClinicalTrials.gov registry entry for NCT00309023 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-663513 is the first listed.
NCT00309023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309023 about?
NCT00309023 is a clinical study titled "Study of BMS-663513 in Patients With Advanced Cancer". This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
What is the current status of trial NCT00309023?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2005-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00309023?
The interventions under investigation include: BMS-663513 (DRUG).
Who is sponsoring clinical trial NCT00309023?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.